Protopic Related Published Studies
Well-designed clinical trials related to Protopic (Tacrolimus Topical)
Topical tacrolimus 0.1% improves symptoms of hand dermatitis in patients treated with a prednisone taper. [2008.07]
Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. [2008.07]
Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression. [2008.04]
A comparative treatment study of topical tacrolimus and clobetasol in oral lichen planus. [2008.02]
Comparison of cutaneous tolerance and efficacy of calcitriol 3 mug g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. [2007.11]
Topical tacrolimus in the treatment of perianal Crohn's disease: Exploratory randomized controlled trial. [2007.03]
The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. [2007.02]
Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. [2007.01]
Topical tacrolimus in the treatment of perianal Crohn's disease: Exploratory randomized controlled trial. [2006.12.19]
Tacrolimus powder in Orabase 0.1% for the treatment of oral lichen planus and oral lichenoid lesions: an open clinical trial. [2006.12]
Tacrolimus ointment in nickel sulphate-induced steroid-resistant allergic contact dermatitis. [2006.11]
Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. [2006.11]
A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment. [2006]
0.3% Tacrolimus gel and 0.5% Tacrolimus cream show efficacy in mild to moderate plaque psoriasis: Results of a randomized, open-label, observer-blinded study. [2006]
Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study. [2005.09]
Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. [2005.08]
Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. [2005.07]
A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. [2005.06]
Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. [2005.03]
Treatment of localized lesions of canine atopic dermatitis with tacrolimus ointment: a blinded randomized controlled trial. [2005.02]
Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. [2005.01]
Tacrolimus ointment is effective for facial and intertriginous psoriasis. [2004.11]
Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study. [2004.10]
Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. [2004.09]
Investigation on the effects of topical therapy with 0.1% tacrolimus ointment (Protopic) on intradermal skin test reactivity in atopic dogs. [2004.08]
Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. [2004.04]
0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. [2004.03]
Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. [2004.02]
Topical tacrolimus 0.1% ointment (protopic) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema. [2003.10]
Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. [2003.09]
Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis. [2003.08]
Safe treatment of head/neck AD with tacrolimus ointment. [2003.06]
A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. [2003.05]
Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. [2002.03]
Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial. [2002.01]
Comparison of the effects of daily applications between topical corticosteroid and tacrolimus ointments on normal skin: evaluation with noninvasive methods. [2002]
Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. [2001.03]
Tacrolimus ointment improves psoriasis in a microplaque assay. [1999.07]
A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. [1998.10]
Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. [1998.09]
A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. [1997.09.18]
Well-designed clinical trials possibly related to Protopic (Tacrolimus Topical)
A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. [2008.07]
A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea. [2008.06]
Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease. [2008.06]
Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial. [2008.05]
Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. [2008.05]
Anti-inflammatory effect of pimecrolimus in the sodium lauryl sulphate test. [2008.04]
[Long-term results of FK 506 eye drops following corneal transplantation] [2008.01]
Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study. [2008]
Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus. [2007.11]
A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. [2007.11]
Pimecrolimus cream (1%) efficacy in perioral dermatitis - results of a randomized, double-blind, vehicle-controlled study in 40 patients. [2007.10]
Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. [2007.08]
Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. [2007.08]
Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. [2007.04]
Pimecrolimus 1% cream in non-specific inflammatory recurrent balanitis. [2007]
Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis. [2007]
Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: Results of a randomized, double-blind, vehicle-controlled study. [2006.11]
1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. [2006.09]
Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. [2006.03]
Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. [2006]
Pimecrolimus and narrowband UVB as monotherapy or combination therapy in children and adolescents with atopic dermatitis. [2006]
A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis. [2005.08]
Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. [2005.06]
Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. [2005.06]
Topical FK506 as immunoprophylaxis after allogeneic penetrating normal-risk keratoplasty: a randomized clinical pilot study. [2005.02]
Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. [2004.12]
Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. [2004.11]
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. [2004.11]
Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. [2004.10]
Better medication adherence results in greater improvement in severity of psoriasis. [2004.10]
Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. [2004.06]
Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. [2004.01]
Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. [2004.01]
Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. [2004]
Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. [2004]
An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. [2003]
Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. [2002.08]
Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. [2002.07]
Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. [2002.04]
Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. [2002]
The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. [2001.03]
The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. [1998.12]
Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. [1998.07]
Clearing of psoriasis by a novel immunosuppressive macrolide. [1996.04]
Other research related to Protopic (Tacrolimus Topical)
Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. [2008.09.06]
Tacrolimus and TGF-beta act synergistically on the generation of Langerhans cells. [2008.07]
Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. [2008.07]
Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. [2008.06]
Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. [2008.06]
Ulcerative lichen planus of the sole: excellent response to topical tacrolimus. [2008.06]
Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty. [2008.05]
Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis. [2008.05]
Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. [2008.04]
Effects of topical application of tacrolimus on acute itch-associated responses in mice. [2008.04]
Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: A randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. [2008.03.20]
Suppressive effects of topical mometasone furoate and tacrolimus on skin prick testing in children. [2008.03]
Tacrolimus-induced hyperpigmentation in a patch of vitiligo. [2008.03]
Tacrolimus: approved and unapproved dermatologic indications/uses-physician's sequential literature survey: part II. [2008.03]
Granuloma faciale successfully treated with topical tacrolimus: a case report. [2008.03]
Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis. [2008.02]
|
